CNBC November 12, 2024
Key Points
– 23andMe on Tuesday reported that second-quarter revenue fell to $44.1 million from $50 million a year earlier.
– The embattled genetics company said Monday that it’s cutting about 200 jobs, or about 40% of its workforce, and discontinuing its therapeutics programs.
– Shares in the company are down 75% this year after losing more than half their value in 2023.
23andMe on Tuesday reported declining revenue in its most recent quarter, a day after the company said it will cut 40% of its workforce and shutter its therapeutics business as part of a business restructuring plan.
The embattled genetics company reported $44.1 million in revenue for the fiscal second quarter, down from $50 million in the same...
Today's Sponsors
Today's Sponsor